The Foundation Dedicated to Discovering a Cure for Neuroendocrine Cancer

Caring for Carcinoid Foundation

Clinical Trials Finder

Syndicate content

The Caring for Carcinoid Foundation offers its Clinical Trials Finder and Patient Resource. This resource will provide the neuroendocrine tumor community with the most up-to-date and comprehensive information on relevant clinical trials in the United States.

With this resource, patients and caregivers may learn about the availability and purpose of existing clinical trials, and access supplemental resources from the Food and Drug Administration, the American Cancer Society and the National Cancer Institute.

By using CFCF's Clinical Trials Finder, patients and caregivers can search our comprehensive neuroendocrine tumor database of clinical trials, which consists of all active clinical trials being conducted in the US for carcinoid, pancreatic neuroendocrine tumors and pheochromocytoma.

Visit our About Clinical Trials page to learn more. For additional information on clinical trials or help using this site, please contact CFCF at 617-948-2514 or info@caringforcarcinoid.org.

Titlesort icon Phase Status Conditions State
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Refractory Neuroblastoma and Pheochromocytoma Not Yet Recruiting Pheochromocytoma MN
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms II Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
Pancreatic Neuroendocrine Tumor
Pheochromocytoma
TX
68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors I/II Enrolling Neuroendocrine Tumor TX
68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors II Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
CA
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer I/II Not Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
TN
90Y-DOTA-tyr3-Octreotide With or Without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors in Children and Young Adults. A Randomized, Placebo Controlled Phase II Trial With Dosimetry Guided Dosing II Not Recruiting Neuroendocrine Tumor IA
A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors Enrolling Neuroendocrine Tumor WI
A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors Enrolling Neuroendocrine Tumor WI
A Dose Escalation, Single Arm, Phase 1b-2 Combination Study of BEZ235 With Everolimus to Determine the Safety, Pharmacodynamics and Pharmacokinetics in Subjects With Advanced Solid Malignancies I/II Enrolling Neuroendocrine Tumor OH
A Double-blind, Randomized Placebo-controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome III Not Recruiting Carcinoid Tumor
CA
KY
LA
MI
MS
NM
OR
PA
TN
VA
WI
A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors II Not Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
Pancreatic Neuroendocrine Tumor
FL
MA
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. II Enrolling Pancreatic Neuroendocrine Tumor
IN
MA
NY
OH
OR
A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours III Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
CA
FL
IL
IA
LA
MA
MN
NY
NC
PA
TN
TX
A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors I Not Recruiting
Carcinoid Tumor
Pancreatic Neuroendocrine Tumor
NY
TX
A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer I Not Recruiting Carcinoid Tumor MN
A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features I Not Recruiting Carcinoid Tumor
AL
CA
DC
IL
IN
MA
MI
MN
MO
NY
OH
PA
TN
TX
WA
WI
A Phase 1 Dose-Escalation Study to Determine the Safety of TH-302 in Combination With Sunitinib in Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors I Enrolling Pancreatic Neuroendocrine Tumor
IN
IA
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors I/II Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
AZ
FL
IA
MN
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma. I/II Enrolling
Neuroendocrine Tumor
Pulmonary Carcinoid
CA
FL
MN
MO
NJ
NY
TN
TX
A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer I/II Not Recruiting Pulmonary Carcinoid
AK
CA
KY
SC
TN
TX
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479 II Enrolling
Carcinoid Tumor
Pulmonary Carcinoid
CA
CO
FL
NY
TN
TX
UT
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma II Not Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
Pancreatic Neuroendocrine Tumor
Pulmonary Carcinoid
MA
TX
A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma II Enrolling Pheochromocytoma
AZ
FL
MD
MI
MN
MO
TX
WI
A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy III Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
AL
CA
FL
IA
KY
LA
MA
NE
NY
TX
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors I
Carcinoid Tumor
Neuroendocrine Tumor
TN

Tell Your Story

Get the facts on pancreatic neuroendocrine cancer

Sign-up for our e-Newsletter.

Tell Your Story

video

Latest Video

Check out the CFCF video library.

Sign-up for our e-Newsletter.

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

video

Latest Video

Check out the CFCF video library.

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

Connect with CFCF online:
FacebookTwitterYouTube

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

Seal Exchange      

Connect with CFCF online:
FacebookTwitterYouTube

Seal Exchange